Imodium Original

Loperamide Hydrochloride, the active ingredient in Imodium Original, is an antidiarrheal presented as an oral tablet for oral use. It reduces intestinal motility and water loss, helping to control acute nonspecific diarrhea and chronic diarrhea associated with inflammatory bowel disease in adults.

GNH USA supplies Imodium Original as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imodium Original is an antidiarrheal that acts on the gastrointestinal tract to reduce stool frequency and improve consistency.

Acute nonspecific diarrhea: provides rapid symptomatic relief by slowing intestinal transit. Chronic diarrhea associated with inflammatory bowel disease: helps control ongoing loose‑stool episodes. Travel‑associated diarrhea: offers over‑the‑counter symptom management for short‑term use.

Loperamide is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Constipation - Abdominal cramping - Nausea - Dry mouth - Dizziness - Headache

Serious or Rare Side Effects: - Severe constipation or paralytic ileus - Allergic reactions such as rash or angioedema - Toxic megacolon in predisposed patients - Cardiac arrhythmias (QT prolongation) - Marked abdominal pain - Hepatic dysfunction

When using Imodium Original, consider the following safety measures. - Short‑term use only: limit treatment to the recommended duration. - Avoid in bacterial dysentery: do not use when diarrhea is caused by invasive organisms. - Pediatric caution: not recommended for children under two years of age. - Hepatic impairment: dose adjustment may be required in severe liver disease. - Concomitant opioids: monitor for additive central effects. - Store at room temperature: keep in the original container, protect from moisture.

Loperamide may interact with other medicines; awareness of the level of interaction helps manage risk.

Major Interactions (Avoid): - Other antidiarrheal agents (e.g., diphenoxylate): risk of excessive opioid effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase loperamide plasma concentrations. - QT‑prolonging drugs (e.g., quinidine, amiodarone): heightened risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Anticholinergic medications: additive constipation. - Sedatives or CNS depressants: monitor for enhanced drowsiness.